Takeda Pharmaceuticals Co. Ltd., of Osaka, Japan, and H. Lundbeck A/S, of Copenhagen, reported data from a head-to-head study of Brintellix (vortioxetine) vs. escitalopram in patients with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction.